Robbins LLP Calls on Gossamer Bio Stockholders to Join Class Action for Recovering Losses

Robbins LLP Encourages Gossamer Bio Stockholders to Take Action

In a recent announcement, Robbins LLP has drawn attention to a class action lawsuit initiated on behalf of investors who acquired shares in Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025, and February 20, 2026. This clinical-stage biotechnology firm is focused on developing treatments for pulmonary conditions, particularly with their product seralutinib aimed at pulmonary hypertension. Unfortunately, the company faced severe setbacks regarding the efficacy of this treatment in a pivotal trial.

During the specified timeframe, the lawsuit alleges that Gossamer Bio misled its investors regarding the results of its PROSERA study. This study was pivotal, as it was designed to assess the impact of seralutinib on patients with pulmonary arterial hypertension. Investors were provided with encouraging information regarding the trial's design and expected outcomes. However, the company concealed significant adverse facts about the study's methodology, especially concerning the placebo effects observed at certain testing locations in Latin America. Such omissions contributed to investors acquiring shares at inflated valuations, only to see them plummet when the truth came to light.

The situation came to a head on February 23, 2026, when Gossamer released results indicating that the primary endpoint for the PROSERA study—improving the six-minute walk distance (6MWD)—was not met. The data showed a +13.3 meter placebo-adjusted improvement, which fell short of the critical 0.025 alpha threshold necessary to deem the study successful. The company attributed this disappointing result partially to the demographics of the enrolled patients in Latin America, who were described as lower-risk individuals that responded unusually well to the placebo treatment. This revelation resulted in a catastrophic decline in Gossamer's stock price—from $2.13 to $0.42 within a few days—a stunning drop of over 80% in value.

For stockholders who might be feeling the adverse impacts of this stock price dip, Robbins LLP is extending an invitation for individuals to participate in this class action. Those interested in possibly leading the class must file their applications by June 1, 2026. Representatives of the class action will advocate for all shareholders impacted by Gossamer Bio’s announcements. Importantly, shareholders do not need to actively participate in the lawsuits to be eligible for potential recovery; they can remain passive members if they so choose.

Robbins LLP operates on a contingency fee basis, meaning shareholders will not incur any fees unless the case results in compensation.

As one of the distinguished firms specializing in shareholder rights, Robbins LLP has been committed to supporting investors since 2002, working to recover their losses and enhance corporate governance. They emphasize their intention to hold executives accountable for discrepancies and poor decisions that affect shareholder investments.

To stay informed on this case, and to receive alerts about any settlements or further developments regarding executive malfeasance, interested individuals can sign up for the Stock Watch service offered by Robbins LLP.

In summary, Gossamer Bio’s investors are advised to explore their options regarding the recent class action lawsuit. It represents a possibility for recovery of losses incurred due to the misrepresentation of crucial data pertaining to the PROSERA study.

For further inquiries or information about the lawsuit, individuals can contact Robbins LLP directly. They can fill out an online form, send an email to attorney Aaron Dumas, Jr., or reach out via phone at (800) 350-6003.